ReviewJournal of pharmacy & bioallied sciences2025
A Systemic Review of Pharmacological Management of Pediatric Obesity.
Review in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic review of influence of ethnicity on efficacy and safety of pharmacotherapy for childhood and adolescent obesity.Clinical and experimental pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a growing need for safe and effective treatment due to the rise in child obesity rates worldwide. The effectiveness and safety of pediatric obesity drugs were reviewed in this systematic review based on international research. Techniques: PubMed, Cochrane Library, and Embase searches were performed to locate pediatric randomized controlled trials of antiobesity medications. Demographics, medication effectiveness, adverse events, and quality of life were all analyzed. Findings: There were 12 studies totaling 4,331 children in the review. The age range of the participants was 8.8 to 16.3 years, and their baseline BMI was between 26.2 and 41.7 kg/m Conclusion: In conclusion, metformin, topiramate, exenatide, liraglutide, and the combination of topiramate and phentermine may lower BMI in children; however, more studies are required to ascertain their long-term safety and effectiveness. Children and adolescents with pediatric obesity may benefit from a tailored, multidisciplinary strategy that incorporates lifestyle modifications, pharmaceutical therapies, and psychological support to assist manage the condition and enhance the health and well-being of those affected.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.